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Objective: To investigate differences in viral shedding in respiratory and fecal samples 
from children with COVID-19. 
Methods: We searched PubMed, SCOPUS, Embase and Web of Science databases to 
identify pediatric studies comparing the pattern of fecal and respiratory shedding of SARS-
CoV-2 RNA. Summary estimates were calculated using random-effects models. 
Results: Four studies reporting data from 36 children were included. A higher proportion 
of children had viral shedding in stools after 14 days of symptoms onset compared to 
respiratory samples (RR= 3.2, 95%CI 1.2 to 8.9, I2 = 51%). Viral RNA shedding was longer in 
fecal samples with a mean difference of approximately 9 days (Mean Difference = 8.6, 
95%CI 1.7 to 15.4, I2 = 77%) compared with respiratory samples. 
Conclusion: SARS-CoV-2 shedding seems to be present in feces for a longer time than in 
the respiratory tract of children. Although fecal SARS-CoV-2 presence in feces do not 
confirm its transmissibility, the high and fast spread of the COVID-19 disease worldwide 
indicate other transmission routes are also plausible. 
 




In late December 2019, the Novel Coronavirus Disease 19 (COVID-19) emerged in Wuhan, 
Hubei Province, China, and rapidly spread to other countries around the world. Although 
COVID-19 is predominantly a respiratory disease mostly transmitted through respiratory 
droplets and skin to mucosae contact, other routes have been proposed, including fecal-
oral transmission.1 
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) uses the 
angiotensin- converting enzyme 2 (ACE2) receptor to invade host cells in the lungs and 
other tissues leading to enhanced release of cytokines and a hyperinflammatory state 
with high morbidity and mortality.2-4 Although children are susceptible to infection, most 
infections are asymptomatic or have mild clinical presentations, raising the possibility 
that children could be an imperceptible source of infection.5 
Recently reports suggest that SARS-CoV-2 RNA remains detectable in the stools of 
children, even after tests of samples from their respiratory tracts have become negative, 
suggesting persistence of fecal viral shedding after symptom resolution.6 We 
systematically investigated the differences in viral shedding patterns of respiratory and 
fecal samples from children with COVID-19. 
Methods 
This study was conducted following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement.7 Searches for studies were performed from 
January 1, 2020 up to April 19, 2020 in the peer-reviewed (PubMed, Embase, Web of 
Science, and Scopus) and grey literature, including Google Scholar and preprint 
publications in the bioRxiv and medRxiv repositories. The reference lists of all eligible 
studies were also scanned to identify additional studies for inclusion. The search terms 
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used were: “COVID-19”, "SARS-CoV-2", “coronavirus”, “pediatrics”, “pediatric”, 
“children”, “neonates”, “newborns”, “shedding”, and “viral load”.
The following elements were used to define eligibility criteria: (1) population: children 
with COVID-19; (2) comparison groups: respiratory versus fecal samples; (3) outcomes: 
viral shedding of SARS-CoV-2 RNA detection by RT-PCT beyond 14 days of symptoms 
onset; (4) study type: observational studies. Duration of viral shedding in respiratory 
swabs and stool samples was also extracted and defined as the number of days from 
symptoms onset to the day when the last specimen in which SARS-CoV-2 was detected. 
We excluded publications with potential overlapping reports based on data collection 
and setting and studies in which data extraction was not possible. In situations of 
studies with potential overlapping data, we selected the study with the most complete 
information. 
Reports were screened in two stages: screening of titles and abstracts followed by the 
retrieval and screening of full-text articles. Two authors extracted data from all reports 
and crosschecked them for accuracy. The risk of bias assessment was conducted using the 
Joanna Briggs Critical Appraisal Tools for Case Series.8 A random-effects meta-analysis 
was used to pool the individual measures from the included studies, and results were 
expressed as the risk ratio (RR) (for persistence of viral shedding) and the mean 
difference (MD) (for the duration of viral shedding) with 95% confidence intervals (CI). 
Statistical heterogeneity was quantified by the I2 index. Analyses were conducted using 
the Review Manager 5.3 (Cochrane IMS, Copenhagen, Denmark). 
Results 
After screening 212 titles and abstracts, five full-text articles were assessed for eligibility. 
Of these, one case series of three patients was excluded. Four studies6,9–11 reporting data 
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from 36 patients (15 boys and 21 girls) were included. All studies had clear objectives and
eligibility criteria and recruited subjects from the same population. However, some of the 
included children remained hospitalized at the time the studies reported the data, and 
whether participants were recruited consecutively is unclear, possibly introducing bias. 
The mean ages ranged from 56 to 91 months. In all studies, children had mild symptoms 
of COVID-19: 58.3% (21/36) presented with fever, 46.7% (14/30) with cough, and 10% 
(3/10) with diarrhea. No child had dyspnea, needed respiratory support or Intensive Care 
Unit (ICU) care, and none died. On admission, SARS-CoV-2 RNA was detected in 94.4% 
(34/36) and 68.8% (22/32) of respiratory and fecal samples by RT-PCR, respectively (see 
Table in Supplemental Digital Content). After 14 days, children were more likely to 
continue shedding SARS-CoV-2 RNA in fecal samples compared to respiratory swabs (RR= 
3.2, 95%CI 1.2 to 8.9, I2 = 51%) (Figure). The duration of SARS- CoV-2 RNA shedding was 
longer in fecal than respiratory samples with a mean difference of 8.6 days (95%CI 1.7 to 
15.4, I2 = 77%). 
Discussion 
This meta-analysis confirms that SARS-CoV-2 RNA is present in feces of a high proportion 
of children with COVID-19 and that viral RNA shedding occurs for a longer time than in the 
respiratory tract, even after RT-PCR tests of the respiratory tract have become negative. 
The COVID-19 pandemic disproportionately impacts adults compared with children. 
Adults have an increased risk of developing severe COVID-19, including the acute 
respiratory distress syndrome, which can result in death, especially among older 
individuals with comorbidities.3,4 In contrast, children are more likely to have 
asymptomatic infections and to experience mild symptoms.5 Children who require 
ambulatory care or hospitalization seem to have more gastrointestinal symptoms than 
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adults, including vomiting and diarrhea.12 These gastrointestinal manifestations thus pose 
important challenges to clinicians at the time of diagnosis, and testing stools of children 
with suspected SARS-CoV-2 infections who have negative RT-PCR tests from respiratory 
samples could aid to confirm infections, especially among children presenting late to the 
clinics. 
During the SARS-CoV-1 outbreak in 2003, fecal shedding was observed in 86% of infected 
individuals during the first 6-14 days of illness and could persist for >30 days from illness 
onset.13 Similarly, the Middle East Respiratory Syndrome-CoV (MERS-CoV) was detected in 
the stools of 15% of patients for up to 24 days after illness onset.14 In this study, SARS-CoV-
2 RNA was detected more frequently in respiratory samples at admission, but fecal samples 
remained RNA-positive well after respiratory samples had become RT-PCR-negative. 
Although it is uncertain at this moment whether these are live virus or just RNA fragments, 
this finding could raise a concern on the isolation policy for the COVID-19 patients, 
particularly during the recovery phase. 
Although our focus was on SARS-CoV-2 shedding in fecal samples of children, similar 
persistent viral RNA shedding is reported in adults.15,16  A retrospective cohort of COVID-19 
in China identified SARS-CoV-2 RNA in the stools of 59% of patients, with a similarly longer 
duration of shedding in stools than in the respiratory samples and peak RNA loads that 
occurred later in stools than in respiratory samples.17 
Our findings should be interpreted with caution. This is a preliminary review of case 
series on fecal SARS-CoV-2 transmission, with findings based on hospitalized children 
who typically have a high viral load. Fecal RNA shedding from asymptomatic children 
who did not require medical care is still unknown. Limited evidence exists on whether 
SARS-CoV-2 RNA shedding from stools is infectious and whether fecal viral shedding 
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plays a role in the dissemination of infection. 
In summary, as SARS-CoV-2 RNA shedding seems to be present in feces for a longer time 
than in respiratory samples. Although fecal SARS-CoV-2 presence in feces does not 
confirm its transmissibility, the rapid and prolific spread of the COVID-19 disease 
worldwide indicates other transmission routes are also plausible. More evidence of SARS- 
CoV-2 RNA in stools is necessary to determine its longer term patterns of fecal excretion 
and whether asymptomatic and mildly ill individuals have persistence of fecal viral 
shedding. 
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Figure. Forest plot showing the risk of persistent viral shedding in fecal samples compared to respiratory tract swabs (A) and mean difference 
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*Data reported in mean and standard deviation. 
 
 
 
